Speyer

Germany

14 total trials 9 recruiting

Filter these 14 trials by phase, condition, sponsor and more.

Open in Search →

A randomized phase III trial assessing iberdomide versus iberdomide plus isatuximab maintenance therapy post autologous hematopoietic stem-c … Recruiting

2023-507402-13-00 5 2024-04-03 Multiple myeloma
AMAZE 12: A research study investigating how well the medicine NNC0487-0111 helps people with excess body weight maintain their weight loss Recruiting

2025-523804-62-00 5 2026-04-28 Obesity
A Trial to Test How AZD0780 Affects Serious Heart, Stroke, or Vascular Problems in Patients with Heart, Stroke or Vascular Disease or at Hig … Recruiting

2025-520519-14-00 5 2025-09-03 Atherosclerotic Cardiovascular Disease
Pre-Operative Treatment in rEseCTable cOlon canceR (PROTECTOR/FIRE-10; AIO-KRK-0620; IAG-VO-0323) Prospective, randomized, open-label, multi … Recruiting

2023-508076-11-00 5 2025-04-01 Colon cancer staged T3-4 and/or nodal positive by CT and/or MRI scan w
C1071032 - MAGNETISMM-32 A PHASE 3, OPEN-LABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMB, POMALIDOMIDE, DEXAMETHASONE (EPd) OR POMAL … Recruiting

2023-507871-23-00 5 2024-05-27 Relapsed/Refractory Multiple Myeloma
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) Recruiting

2023-504031-41-00 5 2024-03-25 ER+/HER2- Early Breast Cancer
CAPTOR-BC: COMPREHENSIVE ANALYSIS OF SPATIAL, TEMPORAL AND MOLECULAR PATTERNS OF RIBOCICLIB EFFICACY AND RESISTANCE IN ADVANCED BREAST CANCE … Recruiting

2022-500764-35-00 6 2022-10-13 Patients with advanced HER2-negative, hormone receptor positive (HER2n
HIPEC/FLOT9 - PREVENT Recruiting

2024-517300-10-01 5 2020-12-17 Resectable diffuse type gastric and gastroesophageal junction Typ II/I
FOLFOX before surgey compared to risk-adapted chemotherapy after surgery in patients with locally advanced rectal cancer and low risk for lo … Recruiting

2024-518077-34-00 5 2020-09-30 locally advanced rectal cancer
Sacituzumab Govitecan in primary HER2-negative breast cancer (SASCIA) Ended recruitment

2023-510390-33-00 5 2020-10-23 HER2-negative breast cancer patients with high relapse risk after stan
A randomized phase III trial assessing the benefit of the addition of isatuximab to lenalidomide / bortezomib / dexamethasone (RVd) inductio … Ended recruitment

2024-513464-26-00 5 2018-10-18 Multiple Myeloma
A randomized phase III non-inferiority trial assessing lenalidomide, bortezomib and dexame-thasone induction therapy with either intravenous … Ended

2024-516300-41-00 5 2023-03-07 Multiple Myeloma
A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes (SURPASS-CV … Ended

2023-507846-96-00 5 2020-06-19 Type 2 Diabetes Mellitus
CIRCULATE Ended

2023-506715-18-00 5 2019-12-04 colon cancer stage II, rectal cancer stage II

Showing 1–14 of 14 trials